New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
07:17 EDTOMEROmeros announces data using OMS721 in patients with aHUS
Omeros Corporation announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome, a form of thrombotic microangiopathy. In February, Omeros reported positive results from its OMS721 Phase 1 clinical trial and, earlier this month, announced submission of an investigational new drug application to the U.S. Food and Drug Administration to initiate a Phase 2 clinical trial in patients with TMA, including patients with aHUS. The data announced resulted from studies conducted in support of the clinical evaluation of OMS721 by Prof. Giuseppe Remuzzi and colleagues Marina Noris and Miriam Galbusera at the Mario Negri Institute for Pharmacological Research in Bergamo, Italy, and the Clinical Research Center for Rare Diseases "Aldo e Cele Daccò" of the same Institute, a European center for collecting and studying TMA samples.
News For OMER From The Last 14 Days
Check below for free stories on OMER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 11, 2014
16:15 EDTOMEROmeros reports Q2 EPS (53c) with items, consensus (52c)
Reports Q2 revenue $45,000, consensus $130,000. Q2 results included $2.5M, or 7c per share of non-cash expenses. The decrease in revenue, year over year, was due to a reduction of activity on NIH grant projects, which resulted in lower revenue being recognized.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use